Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Results of a population screening intervention for tuberculosis in a Nunavik village, Quebec, 2015-2016.

Dion R, Brisson M, Proulx JF, Zoungrana H.

Can Commun Dis Rep. 2018 Oct 4;44(10):257-263. doi: 10.14745/ccdr.v44i10a04. eCollection 2018 Oct 4.

2.

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.

Canfell K, Kim JJ, Kulasingam S, Berkhof J, Barnabas R, Bogaards JA, Campos N, Jennett C, Sharma M, Simms KT, Smith MA, Velentzis LS, Brisson M, Jit M.

Papillomavirus Res. 2019 Sep 7:100184. doi: 10.1016/j.pvr.2019.100184. [Epub ahead of print]

3.

Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.

Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Bénard É, Brisson M.

CMAJ. 2019 Aug 26;191(34):E932-E939. doi: 10.1503/cmaj.190274.

4.

Guidelines for multi-model comparisons of the impact of infectious disease interventions.

den Boon S, Jit M, Brisson M, Medley G, Beutels P, White R, Flasche S, Hollingsworth TD, Garske T, Pitzer VE, Hoogendoorn M, Geffen O, Clark A, Kim J, Hutubessy R.

BMC Med. 2019 Aug 19;17(1):163. doi: 10.1186/s12916-019-1403-9.

5.

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Drolet M, Bénard É, Pérez N, Brisson M; HPV Vaccination Impact Study Group.

Lancet. 2019 Aug 10;394(10197):497-509. doi: 10.1016/S0140-6736(19)30298-3. Epub 2019 Jun 26.

PMID:
31255301
6.

An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool.

Bellan SE, Eggo RM, Gsell PS, Kucharski AJ, Dean NE, Donohue R, Zook M, Edmunds WJ, Odhiambo F, Longini IM Jr, Brisson M, Mahon BE, Henao-Restrepo AM.

Vaccine. 2019 Jul 18;37(31):4376-4381. doi: 10.1016/j.vaccine.2019.06.019. Epub 2019 Jun 24.

7.

Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study.

Bolotin S, Severini A, Hatchette T, McLachlan E, Savage R, Hughes SL, Wang J, Deeks SL, Wilson S, Brisson M, Halperin SA, Gubbay J, Mazzulli T, Serhir B, Ward BJ, Crowcroft N.

Hum Vaccin Immunother. 2019 Jul 16:1-9. doi: 10.1080/21645515.2019.1619402. [Epub ahead of print]

PMID:
31184979
8.

Validation of an Magnetic Resonance Imaging Acquisition and Review Protocol for Alzheimer's Disease and Related Disorders.

Asselin A, Potvin O, Bouchard LO, Brisson M, Duchesne S.

Can Assoc Radiol J. 2019 May;70(2):172-180. doi: 10.1016/j.carj.2018.10.008. Epub 2019 Mar 17.

PMID:
30894287
9.

In Reply to "Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol".

Proulx LC, Villeneuve É, Genest M, Francoeur I, Brisson M, Gosselin S.

Am J Crit Care. 2019 Mar;28(2):97-98. doi: 10.4037/ajcc2019690. No abstract available.

PMID:
30824510
10.

Global elimination of cervical cancer as a public health problem.

Brisson M, Drolet M.

Lancet Oncol. 2019 Mar;20(3):319-321. doi: 10.1016/S1470-2045(19)30072-5. Epub 2019 Feb 19. No abstract available.

PMID:
30795952
11.

Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature.

Drolet M, Bénard É, Jit M, Hutubessy R, Brisson M.

Value Health. 2018 Oct;21(10):1250-1258. doi: 10.1016/j.jval.2018.03.014. Epub 2018 May 24. Review.

13.

Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.

Markowitz LE, Drolet M, Perez N, Jit M, Brisson M.

Vaccine. 2018 Aug 6;36(32 Pt A):4806-4815. doi: 10.1016/j.vaccine.2018.01.057. Epub 2018 May 22. Review.

14.

Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus.

Jit M, Brisson M.

Int J Cancer. 2018 Jul 15;143(2):317-323. doi: 10.1002/ijc.31321. Epub 2018 Mar 1.

15.

Predictors of clinical success in runners with patellofemoral pain: Secondary analyses of a randomized clinical trial.

Esculier JF, Bouyer LJ, Dubois B, Leblond J, Brisson M, Chau L, Roy JS.

J Sci Med Sport. 2018 Aug;21(8):777-782. doi: 10.1016/j.jsams.2018.01.006. Epub 2018 Jan 31.

PMID:
29395632
16.

Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.

Simms KT, Laprise JF, Smith MA, Lew JB, Caruana M, Brisson M, Canfell K.

Lancet Public Health. 2016 Dec;1(2):e66-e75. doi: 10.1016/S2468-2667(16)30019-6. Epub 2016 Nov 29.

17.

Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models.

Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C.

Lancet Public Health. 2016 Nov;1(1):e8-e17. doi: 10.1016/S2468-2667(16)30001-9. Epub 2016 Sep 27. Review.

18.

The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation.

Drolet M, Laprise JF, Brotherton JML, Donovan B, Fairley CK, Ali H, Bénard É, Martin D, Brisson M.

J Infect Dis. 2017 Dec 5;216(10):1205-1209. doi: 10.1093/infdis/jix476.

19.

Modelling multi-site transmission of the human papillomavirus and its impact on vaccination effectiveness.

Lemieux-Mellouki P, Drolet M, Jit M, Gingras G, Brisson M.

Epidemics. 2017 Dec;21:80-87. doi: 10.1016/j.epidem.2017.08.001. Epub 2017 Aug 25.

21.

The aeromedical physician assistant.

Radi J, Brisson M, Line M.

JAAPA. 2016 Dec;29(12):42-44.

PMID:
27898553
22.

Effect of HPV on cervical cancer screening in Alberta.

Brisson M, Drolet M, Bénard É, Kreimer AR.

CMAJ. 2016 Oct 4;188(14):1035. doi: 10.1503/cmaj.1150121. No abstract available.

23.

Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review.

Gingras G, Guertin MH, Laprise JF, Drolet M, Brisson M.

PLoS One. 2016 Sep 30;11(9):e0163880. doi: 10.1371/journal.pone.0163880. eCollection 2016.

24.

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.

Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL.

Emerg Infect Dis. 2016 Oct;22(10):1732-40. doi: 10.3201/eid2210.160675. Review.

25.

Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis.

Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M.

J Infect Dis. 2016 Sep 1;214(5):685-8. doi: 10.1093/infdis/jiw227. Epub 2016 May 27.

26.

Workplace air quality: International consensus standards.

Lee EG, Ashley K, Breuer D, Brisson MJ, Harper M, Thom C.

J Occup Environ Hyg. 2016 Jul;13(7):D111-7. doi: 10.1080/15459624.2016.1163710. No abstract available.

27.

Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada.

Drolet M, Deeks SL, Kliewer E, Musto G, Lambert P, Brisson M.

Vaccine. 2016 Apr 7;34(16):1874-80. doi: 10.1016/j.vaccine.2016.02.069. Epub 2016 Mar 5.

PMID:
26954465
28.

Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.

Brotherton JM, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S.

Int J Cancer. 2016 Aug 1;139(3):510-7. doi: 10.1002/ijc.30063. Epub 2016 Mar 22. Review.

29.

Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.

Chesson HW, Laprise JF, Brisson M, Markowitz LE.

J Infect Dis. 2016 Jun 1;213(11):1694-700. doi: 10.1093/infdis/jiw046. Epub 2016 Feb 9.

30.

Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior.

Baussano I, Lazzarato F, Brisson M, Franceschi S.

Emerg Infect Dis. 2016 Jan;22(1):18-23. doi: 10.3201/eid2201.150791.

31.

Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus.

Lemieux-Mellouki P, Drolet M, Brisson J, Franco EL, Boily MC, Baussano I, Brisson M.

Epidemiol Infect. 2016 May;144(7):1490-9. doi: 10.1017/S0950268815002915. Epub 2015 Nov 20.

32.

Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.

Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC, Markowitz LE.

J Natl Cancer Inst. 2015 Oct 4;108(1). pii: djv282. doi: 10.1093/jnci/djv282. Print 2016 Jan.

33.

Fewer than three doses of HPV vaccine.

Jit M, Laprise JF, Choi YH, Brisson M.

Lancet Oncol. 2015 Sep;16(9):e423-e424. doi: 10.1016/S1470-2045(15)00229-6. No abstract available.

PMID:
26370345
34.

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M.

Lancet Infect Dis. 2015 May;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4. Epub 2015 Mar 3. Review.

35.

Prevalence and Frequency of Heterosexual Anal Intercourse Among Young People: A Systematic Review and Meta-analysis.

Owen BN, Brock PM, Butler AR, Pickles M, Brisson M, Baggaley RF, Boily MC.

AIDS Behav. 2015 Jul;19(7):1338-60. doi: 10.1007/s10461-015-0997-y. Review.

36.
37.

Changing inequalities in cervical cancer: modeling the impact of vaccine uptake, vaccine herd effects, and cervical cancer screening in the post-vaccination era.

Malagón T, Drolet M, Boily MC, Laprise JF, Brisson M.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):276-85. doi: 10.1158/1055-9965.EPI-14-1052. Epub 2014 Nov 7.

38.

Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.

Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagón T, Brisson M.

Vaccine. 2014 Oct 7;32(44):5845-53. doi: 10.1016/j.vaccine.2014.07.099. Epub 2014 Aug 12.

39.

Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM.

Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos LL, DE Serres G.

Epidemiol Infect. 2015 Apr;143(6):1332. doi: 10.1017/S0950268814002088. Epub 2014 Aug 13. No abstract available.

PMID:
25115531
40.

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.

Jit M, Brisson M, Portnoy A, Hutubessy R.

Lancet Glob Health. 2014 Jul;2(7):e406-14. doi: 10.1016/S2214-109X(14)70237-2. Epub 2014 Jun 9.

41.

Clinical reasoning: a puzzling case of amnesia.

Bereznyakova O, Milot G, Brisson M, Laforce R Jr.

Neurology. 2014 Aug 5;83(6):e73-6. doi: 10.1212/WNL.0000000000000676. No abstract available.

PMID:
25092930
42.

Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?

Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M.

Vaccine. 2014 May 30;32(26):3237-42. doi: 10.1016/j.vaccine.2014.03.098. Epub 2014 Apr 13.

PMID:
24726246
43.

The spore-associated protein BclA1 affects the susceptibility of animals to colonization and infection by Clostridium difficile.

Phetcharaburanin J, Hong HA, Colenutt C, Bianconi I, Sempere L, Permpoonpattana P, Smith K, Dembek M, Tan S, Brisson MC, Brisson AR, Fairweather NF, Cutting SM.

Mol Microbiol. 2014 Jun;92(5):1025-38. doi: 10.1111/mmi.12611. Epub 2014 Apr 24.

44.

Health technology assessment in an argentinean province: adapting existing tools.

Brisson ME, Schapochnik N.

Int J Technol Assess Health Care. 2014 Jan;30(1):121-7. doi: 10.1017/S0266462313000627. Epub 2014 Feb 6.

PMID:
24503226
45.

Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.

Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M.

Int J Cancer. 2014 May 1;134(9):2264-8. doi: 10.1002/ijc.28541. Epub 2013 Oct 31.

46.

Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?

Drolet M, Boily MC, Van de Velde N, Franco EL, Brisson M.

PLoS One. 2013 Jun 26;8(6):e67072. doi: 10.1371/journal.pone.0067072. Print 2013.

47.

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.

Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.

Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3.

PMID:
23830974
48.

Response.

Boily MC, Brisson M, Drolet M, Malagón T.

J Natl Cancer Inst. 2013 May 15;105(10):750-1. Epub 2013 May 2. No abstract available.

PMID:
23814885
49.

Response.

Brisson M, Drolet M, Boily MC, Malagón T, Franco EL, Laprise J, Van de Velde N, Mayrand MH, Kliewer EV, Coutlée F.

J Natl Cancer Inst. 2013 May 1;105(9):664-5. No abstract available.

PMID:
23767055
50.

Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination.

Drolet M, Boily MC, Greenaway C, Deeks SL, Blanchette C, Laprise JF, Brisson M.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):641-52. doi: 10.1158/1055-9965.EPI-12-1173.

Supplemental Content

Loading ...
Support Center